To evaluate the safety, tolerability, and efficacy of GBT021601 in adult participants with SCD to determine an optimal dose.
Thank you for your interest, but this study is recruiting by invitation only.
North Carolina (Statewide)
Jane Little
Medicine-Hematology
Clinical or Medical
Interventional
Blood Conditions
Rare Diseases
23-0416
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
